OBJECTIVE To determine the efficacy and efficiency of two fixed doses of recombinant follicle-stimulating hormone (FSH) in controlled ovarian hyperstimulation. DESIGN Randomized, double-blind clinical trial. SETTING Fifteen IVF clinics in Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. PATIENT(S) Women between 30 and 39 years of age undergoing IVF or intracytoplasmic sperm inje...

background: intrauterine insemination (iui) is the first therapeutic step in assisted reproductive techniques and many factors, including male and female infertility and technique-dependent factors, have been reported to influence pregnancy rates after iui. methods: we carried out this retrospective study on 1201 couples undergoing 3012 intrauterine insemination cycles during 2002 to 2009. preg...

1. Halupczok J, Kluba‐Szyszka A, Bidzinska‐Speichert B, Knychalski B. Ovarian hyperstimulation caused by gonadotroph pituitary adenoma – Review. Adv Clin Exp Med 2015;24:695‐703. 2. Roberts JE, Spandorfer S, Fasouliotis SJ, Lin K, Rosenwaks Z. Spontaneous ovar ian hypers t imula t ion caused by a follicle‐stimulating hormone‐secreting pituitary adenoma. Fertil Steril 2005;83:208‐10. 3. Pentz‐Vi...

This article is a systematic review of the literature on utilization of gonadotrophin-releasing hormone antagonists (GnRH-ant) for ovarian stimulation for IVF in special patient groups. Summarized by meta-analysis are the data from randomized controlled trials (RCT) in which GnRH-agonist (GnRH-a) and GnRH-ant were compared (eight RCT for poor response, four RCT for PCOS). Also reviewed are the ...

Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication that is associated with modern techniques for in vitro fertilization. Extensive efforts have been made to understand the pathophysiology and to improve the management of this entity. The severe and life-threatening forms of the ovarian hyperstimulation syndrome are still challenging for critical care physicians. This article...

pituitary suppression by depot gnrh agonist may be excessive for ovarian stimulation. this study compares the efficacy of a single half-dose depot triptorelin and reduced-dose daily buserelin in a long protocol icsi/et. methods: a total of 182 patients were randomized into two groups using sealed envelopes. pituitary desensitization was obtained in group 1 (91 patients) with half-dose (1.87 mg)...